#4 - AbbVie (NYSE:ABBV)
A different way to invest in the healthcare sector is through the biopharmaceutical industry. This can steer investors to unprofitable start-ups with the potential for meteoric gains “if” they can get a candidate approved. A safer choice is a company with a proven pipeline of commercially available drugs, such as AbbVie Inc. (NYSE: ABBV).
ABBV stock has delivered a total return of 219% to investors over the past five years. Much of that has to do with its blockbuster drug, Humira. The patent protection on Humira has expired, but the company is seeing robust growth in new drugs such as Skyrizi and Rinvoq to pick up the slack.
Looking to the future, AbbVie has a pipeline of over 90 drug candidates, with more than 50 in mid- or late-stage trials in areas such as immunology, oncology, and neuroscience.
AbbVie is another Dividend King on this list of stocks, and it’s an impressive one at that. The yield as of October 16, 2024, is 3.26%. Plus, the stock has increased its annual payout by an average annual rate of 7.84% over the past three years. That’s nearly triple the rate of inflation.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More - Current Price
- $166.58
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 18 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $203.37 (22.1% Upside)
